Patent Issued for Cycloalkane-1,3-diamine derivative (USPTO 12060365).

Daiichi Sankyo Company Limited has been granted a patent for a cycloalkane-1,3-diamine derivative, a compound used in the treatment of acute myelogenous leukemia (AML) or acute lymphocytic leukemia (ALL). The patent explains the need for a low-molecular compound that can inhibit the interaction between menin and an MLL protein. It also includes claims for a pharmaceutical composition containing the compound and a selection of drugs for treating or preventing diseases dependent on this interaction. The patent provides comprehensive information about the compound's structure, its various forms, and its use in pharmaceutical compositions, including its combination with other drugs like Venetoclax, a DNA methyltransferase inhibitor, or a pyrimidine antimetabolite. [Extracted from the article]